Executive Leadership

Partnership: It’s what turns services into solutions

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings, CEO, Frontage Laboratories
Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings, CEO, Frontage Laboratories

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

 

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Zhihe (Zeke) Li, M.D., Ph.D.

Zhihe (Zeke) Li, M.D., Ph.D.

Senior Vice President, Frontage Laboratories, Executive Director of the Board
Zhihe (Zeke) Li, M.D., Ph.D.

Zhihe (Zeke) Li, M.D., Ph.D.

Senior Vice President, Frontage Laboratories, Executive Director of the Board

Dr. Zhihe (Zeke) Li is responsible for global project management functions and the company’s corporate strategy. As one of the founders and board members of Frontage, Dr. Li has more than 20 years of related experience that began with post-doctoral training at the National Institutes of Health. Prior to Frontage, he served as Group Leader, Preclinical and Pharmacology for Scios Inc., a Johnson and Johnson company. In recent years, Dr. Li has interacted extensively with Chinese biopharmaceutical companies on novel and generic development projects. With in-depth experience in research and development of small molecules, peptides and protein drugs, he has authored and co-authored more than 40 scientific papers and patents.

Dr. Li received his medical degree and a master’s degree in pathology from Norman Bethune University of Medical Sciences in China. He earned a doctor of philosophy degree in pathology from McGill University.

linkedin logo 150x150 - Zhihe (Zeke) Li, M.D., Ph.D.

Read Full Bio
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)

Mr. Wang has more than 27 years of extensive experience in financial service and accounting aspect, include corporate finance and treasury management, corporate accounting, compliance, internal control and corporate budgetary management. Mr. Wang is the Chief Financial Officer of the Company and is responsible for the management of all aspects of the Group’s finance and treasury matters.  Prior to joining Frontage in October 2020, Mr. Wang was the Chief Financial Officer of Frontida Biopharm, Inc., a contract development and manufacturing organization in the United States of America. Previously, he was the Chief Financial Officer and the Director of the Board of Sky Solar Holdings, Ltd. a NASDAQ listed company.  Before that, he served as finance director or controller in different multinational companies, mainly in the Asia Pacific area.

 

Mr. Wang is a professional accountant, having been a member of the China Institute of Certified Public Accountant since August 1995.  Mr. Wang was awarded an Executive Master of Business Administration by Washington University in St. Louis in December 2004.  In July 1993, he was awarded a Bachelor’s degree in Accounting by University of Shanghai for Science and Technology.

linkedin logo 150x150 - Andrew Wang

Read Full Bio
Glenn Washer

Glenn Washer

President, Frontage Laboratories North America and Executive Vice President for Global Safety and Toxicology
Glenn Washer

Glenn Washer

President, Frontage Laboratories North America and Executive Vice President for Global Safety and Toxicology

Glenn Washer, holds dual roles at Frontage. As the President of Frontage Laboratories, North America he is responsible for operational and financial performance of the North American businesses. As the Executive Vice President for Global Safety and Toxicology, Glenn is responsible for the overall leadership and the strategic global growth of the Safety/Toxicology business at Frontage Laboratories.

Glenn has over 35 years experience in the drug development industry.  Prior to joining Frontage, he served as President of Charles River’s Canadian preclinical businesses, and as Senior Vice President responsible for Charles River’s North America Safety Assessment business unit.  Previously he served as VP Toxicology at ITR Laboratories and at LAB Research Inc.

Glenn graduated from McGill University in 1989 and was Certified as a Diplomat of the American Board of Toxicology in 1999.  He has served as a Faculty Member with the Washington-DC-based Pharmaceutical Education & Research Institute, served on the Editorial Board for the International Journal of Toxicology, and has lectured on toxicology for the Society of Toxicology, the Drug Information Association, the Society of Quality Assurance, McGill University and Universite de Montreal.  In addition, he has served as a board member for multiple life-sciences industry organizations, and is certified as a corporate director by the Institute of Corporate Directors.

linkedin logo 150x150 - Glenn Washer

Read Full Bio
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services

With more than 20 years of pharmaceutical and biotech industrial experience, Dr. Wang is responsible for the Global CMC (Chemistry Manufacture & Control) Services at Frontage, including analytical services, formulation development, and manufacturing of GLP preclinical tox batches & GMP clinical trial materials. Products includes oral formulations, topical and sterile injections & ophthalmic formulations for IND, NDA and ANDA filings. Prior to joining Frontage in February 2007, Dr. Wang served as the director of Analytical Chemistry at NovaDel Pharma Inc., where she led teams providing support for NDA product development, clinical supply manufacturing, CMC sections of 505(b)(2) filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed Pharmaceutical Analysis and Control department at Therics Inc. to support 3D printing product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.

Dr. Wang earned a PhD degree in Chemistry from Iowa State University, followed by postdoctoral research at the University of Chicago. She received a MS in Chemical Engineering from China Institute of Atomic Energy and a BS in Chemistry from Peking University in China.

linkedin logo 150x150 - Dongmei Wang, Ph.D.

Read Full Bio
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Global Head Bioanalytical and Biologics Services
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Global Head Bioanalytical and Biologics Services

As Executive Vice President, Bioanalytical and Biologics Services, Dr. John Lin leads operations for the company’s global bioanalytical labs. Before joining Frontage, he served as a business leader in AstraZeneca’s global drug metabolism and pharmacokinetics (DMPK) division. Prior to AstraZeneca, Dr. Lin was Laboratory Director for Avantix Laboratories.

With more than 20 years of experience, Dr. Lin’s current research focus is in the area of bioanalytical method development and validation, dry blood spot (DBS) sampling with LC-MS/MS analysis, and biomarker quantification using LC-MS/MS. He has contributed to more than 20 research publications covering the development and validation of LC-MS/MS methods for the determination of small and large molecules in biological matrices, four book chapters and one technical patent. He is the invited reviewer for several international journals including the Journal of Pharmaceutical Biomedical Analysis (JPBA) and Journal of Chromatography B (JCB).

Dr. Lin earned a doctor of philosophy degree in analytical chemistry from Dalhousie University in Canada. He received a master’s degree in analytical chemistry from Yunnan University and a bachelor of science degree in chemistry from Fuzhou Branch School of Jiangxi Normal College. Dr. Lin completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center of the Ohio State University.

linkedin logo 150x150 - John Lin, Ph.D.

Read Full Bio
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services

Dr. Abdul Mutlib is Executive Vice President of Drug Metabolism and Pharmacokinetics, and leads operations for this service group.  Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck.  With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.

Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships at Universities of Washington and British Columbia.

linkedin logo 150x150 - Abdul Mutlib, Ph.D.

Read Full Bio
Lisa Diamond, Ph.D.

Lisa Diamond, Ph.D.

President, Frontage Clinical Services
Lisa Diamond, Ph.D.

Lisa Diamond, Ph.D.

President, Frontage Clinical Services

As President of Frontage Clinical Services since 2018, Dr. Diamond leads operations for the US Clinical service group. Dr. Diamond joined Frontage as Director of Clinical Affairs in 2005, and manages cross-functional teams, including Data Management, Programming, Biostatistics, Project Management and Medical Writing, provides Clinical Operations oversight and supports Business Development and Client Relations. Her prior positions in academia, small biopharmaceutical companies, and at Bristol-Myers Squibb contribute to a broad experience base in research and development, and preclinical and clinical research.

Dr. Diamond earned a Doctor of Philosophy and Master of Science degrees in Basic Medical Sciences from New York University (New York, NY), and a Bachelor of Science degree in Biology from Suffolk University (Boston, MA). She completed post-doctoral training at Princeton University (Princeton, NJ), and is an adjunct professor at Rider University (Lawrenceville, NJ).

Read Full Bio
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations
Yining Qi, MBA

Yining Qi, MBA

President, Frontage's China Operations

Before joining Frontage, Dr Qi served as Vice President of R&D, RA and Medical and President of research institute for Hebei Changshan Biochemical Pharmaceutical Company Inc.  Prior to that, he was global Senior VP of Operation & General Manager (Taicang) of Crown Bioscience Inc. and served as Board Chairman and General Manager of Taicang-Crownbio Biopharmaceutical Analysis, Inc. Dr. Qi has held several other notable roles including: Executive Director of Technical Operation, Client Services and Project Management of WuXi AppTec (Suzhou) Co., Ltd.; Research Fellow, Group Leader, Laboratory Technical Operations (LTO) Safety Assessment of Merck Research Laboratories (MRL); Sr. Clinical Project Manager/DBA of Becton, Dickinson and Company; Director of Department of Toxicology and Pharmacology, Beijing Institute for Drug Control of NMPA Beijing Branch.                                  

Dr. Qi received a Master of Business Administration in Pharmaceutical Management from Rutgers University in 2007, a Master of Science in Computer Science from Southeastern University in 1999, a Master of Public Health from Shanxi Medical University in 1991, and a Bachelor of Medicine (M.D. equivalent) from Shanxi Medical University in 1984.                                                                

“It’s my great honor and pleasure to join Frontage,” said Dr. Qi. “I believe that my past R&D and management experience will further help to enhance Frontage’s ability to provide high quality and efficient service for pharmaceutical companies and R&D institutions.”

Read Full Bio
Richard Fischetti

Richard Fischetti

Vice President and General Counsel
Richard Fischetti

Richard Fischetti

Vice President and General Counsel

Richard Fischetti, Vice President and General Counsel, has extensive experience in corporate law relating to life sciences companies.  Prior to joining Frontage, Richard was a Partner in the Mergers & Acquisitions Group of Shearman & Sterling LLP, a multinational law firm headquartered in New York City, where he practiced for over a decade.  While at Shearman, Richard led numerous strategic transactions for both public and private companies, including mergers, acquisitions and joint ventures,  as well as advising on matters related to securities laws, corporate governance and shareholder activism.  Much of his experience involved advising various life sciences companies.

 

Richard earned his BA with highest honors and JD with high honors from Rutgers University.

Read Full Bio
Matt Vaneman

Matt Vaneman

Senior Vice President, Operational Excellence
Matt Vaneman

Matt Vaneman

Senior Vice President, Operational Excellence

Matthew Vaneman, Senior Vice President for Operational Excellence, has over 20 years of experience in the drug development industry.  Prior to joining Frontage, Matt served as Vice President of Operational Excellence and Site Director at Charles River Laboratories. In these roles, Matt was responsible for strategic resource planning, post-merger integration activities, global harmonization and efficiency programs. As Site Director his responsibilities included oversight of four preclinical laboratories in various regions of North America focused on Pathology, Reproductive and Developmental Toxicology, Photobiology and General Safety Testing. Matt also served as Head of Regulatory Compliance and Operations for Argus Research Laboratories.

Matt graduated from Philadelphia College of Pharmacy and Science in 1997.  Matt has been active in multiple professional societies and most recently has lectured for the Society of Quality Assurance and the Philadelphia Manufacturing Summit on efficiency measurement, process improvement, regulatory compliance, employee retention and generational acceptance and communication. Matt has also been active in multiple community activities such as STEM outreach, athletic coaching and youth leadership training.

Read Full Bio
Larry Veal

Larry Veal

Senior Vice President, Sales and Marketing, North America
Larry Veal

Larry Veal

Senior Vice President, Sales and Marketing, North America

Frontage Laboratories, Inc., announces the appointment of Larry Veal, Senior Vice President of North America Sales and Marketing. In this role, Larry will be responsible for Sales & Marketing for Frontage’s full portfolio of services, including Discovery, DMPK, Bioanalysis, Central Laboratories, Safety & Toxicology, Chemistry, Manufacturing & Controls, and Clinical. As a member of the executive leadership team, reporting to Glenn Washer, President, Frontage Laboratories North America, Larry will work closely with Frontage’s business units to develop and implement strategies to leverage our broad range of services to target key customer segments and capitalize on our strong reputation for scientific and operational excellence.

Larry has over 35 years in the pharmaceutical and CRO industry working in business development, management, marketing, and new product development. Prior to joining Frontage, Larry served as Vice President of North America Sales for NAMSA, a medical device contract research organization. In this role, Larry oversaw 36 sales-focused employees with a P&L of over $120 million. Prior to NAMSA, Larry was Global Vice President of Sales at ICON Clinical Research’s Commercialization and Late Phase Business Unit.

Larry has spent over 25 years in the clinical research space, and prior to that, over 12 years in the Pharmaceutical industry in a variety of roles including sales, product development, training and management in companies such as Roche Laboratories and Johnson and Johnson.

Larry graduated from Augusta University in 1985 with a BBA in Business Administration, emphasis in Marketing. Larry is a member of several industry organizations and has spoken and chaired sessions at multiple conferences including DIA, NCDEU and SCOPE.

Mr. Washer remarked that, “Larry’s joining brings a wealth of experience and expertise which marks our commitment to our customers, our staff and our shareholders to continue to strengthen and mature our organization’s leadership as we aggressively expand our business both organically and through acquisitions. I am confident that Larry will make significant contributions to our continuing success.”

 

linkedin logo 150x150 - Larry Veal

Read Full Bio
Suden Rao, Ph.D.

Suden Rao, Ph.D.

Senior Vice President, Human Resources, North America
Suden Rao, Ph.D.

Suden Rao, Ph.D.

Senior Vice President, Human Resources, North America

Dr. Sudendra (Suden) Rao joins Frontage as Senior Vice President, Human Resources, North America. In this new role, Suden will be leading the HR teams across all of Frontage’s North American sites.

His broad mandate will be to lead the transition of our HR team to an expanded organization, scaled to meet the growing needs of our rapidly growing businesses. Working closely and collaboratively with the business units and other functional support groups, his primary areas of focus will be implementation of HR best practices, processes, and systems in the areas of employee recruiting, training and development, retention and engagement.

Suden brings over 25 years of US and global human resources leadership experience with entrepreneurial startup to world-class Fortune 500 organizations. Suden has worked with pharmaceutical, biotechnology, CRO, medical devices and healthcare organizations known for HR best practices and recognized among the Best Companies to Work For. Most recently he was the Chief HR Officer of Cadila Pharmaceuticals, supporting operation, transformation, and exponential growth across Americas, EMEA and Asia. Previously he has held US and global HR leadership roles at DaVita and Quest Diagnostics, both Fortune 500 healthcare leaders, where he successfully led organizational restructuring, change management and automation and digital transformation of HR, supporting organic and M&A growth.

Suden received a PhD in HRD from the Colorado State University, USA and MA in Economics and Bachelor’s in Law from India, and a Gold Medal in Training and Development. He is a frequently invited speaker at international HR and business forums.

 

linkedin logo 150x150 - Suden Rao, Ph.D.

Read Full Bio